Shire (LON:SHP)‘s stock had its “buy” rating reiterated by analysts at Deutsche Bank in a report issued on Monday.
Other equities analysts have also issued reports about the company. Shore Capital reiterated a “buy” rating on shares of Shire in a research report on Thursday, October 26th. Berenberg Bank reduced their price objective on Shire from GBX 6,000 ($80.75) to GBX 5,900 ($79.41) and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Jefferies Group reiterated a “buy” rating on shares of Shire in a research report on Tuesday, August 22nd. Citigroup reiterated a “buy” rating and set a GBX 6,300 ($84.79) price objective on shares of Shire in a research report on Tuesday, August 22nd. Finally, Kepler Capital Markets reiterated a “buy” rating and set a GBX 4,600 ($61.91) price objective on shares of Shire in a research report on Wednesday, November 1st. Four investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of GBX 5,277.78 ($71.03).
Shire (SHP) opened at GBX 3,727 ($50.16) on Monday. Shire has a 1 year low of GBX 3,435.50 ($46.24) and a 1 year high of GBX 5,067 ($68.20).
In other Shire news, insider Anne Minto acquired 190 shares of the company’s stock in a transaction on Friday, September 29th. The stock was acquired at an average price of GBX 3,785 ($50.94) per share, for a total transaction of £7,191.50 ($9,679.00).
COPYRIGHT VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/11/shires-shp-buy-rating-reiterated-at-deutsche-bank.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.